SavedAdd your journal

Journals / International Journal of Chemistry and Technology / 2019 / Volume: 3 Issue: 2

Inhibition effects of commonly used some antibacterial and antiviral drugs on purified human serum paraoxonase-1 (hPON1)

Hakan Soyut0000-0002-0361-7458
Pages
—
Publication Date
2019-12-31
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

IC50 values were determined.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:hPON1 is an enzyme from the group of A-esterases which is capable of hydrolyzing the active metabolite paraoxon of parathion, an organic phosphorus insecticide.
📊
Key Findings & Data:In this study, human serum PON1 was purified using three simple biochemical purification techniques.
💡
Conclusion & Impact:IC50 values were determined.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Paraoxonase · enzyme inhibition · antibacterial drug

Abstract

hPON1 is an enzyme from the group of A-esterases which is capable of hydrolyzing the active metabolite paraoxon of parathion, an organic phosphorus insecticide. It is an important liver enzyme that plays a protective role against the hydrolysis of HDL-induced organophosphate agents and nerve gases, oxidation of LDL, formation of lipid peroxides and bacterial endotoxins. The fact that oxidation of LDL constitutes the initial stage of the atherosclerosis process reveals the importance of the antioxidant properties of the enzyme. In this study, human serum PON1 was purified using three simple biochemical purification techniques. Furthermore, the in vitro effects of some antibacterial and antiviral drugs on human serum PON1 enzyme activity were examined. IC50 values were determined.

🔖

Cite This Article

Soyut, H. (2019). Inhibition effects of commonly used some antibacterial and antiviral drugs on purified human serum paraoxonase-1 (hPON1). International Journal of Chemistry and Technology, Volume: 3 Issue: 2. https://doi.org/10.32571/ijct.651334

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Bandettini di Poggio, M.; Anfosso, S.; Audenino, D.; Primavera, A. J. Clin. Neurosci. 2011, 18, 313-318.
  2. Giamarellos-Bourboulis, E.J.; Antonopoulou, A.; Raftogiannis, M. Koutoukas P, Tsaganos, T., Tziortzioti, V., Panagou, C., Adamis, T., Giamarellou, H. BMC Infect. Dis. 2006, 21, 31.
  3. Cheathama, S. C.; Shea, K. M.; Healy, D. P.; Humphrey, M. L.; Fleming, M. R.; Wack, M. F.; Smith, D. W.; Sowinski, K. M.; Kays, M. B. Int. J. Antimicrob. AG. 2011, 37 (1), 46-50.
  4. Singh, A. K.; Quraishi, M. A. Corros. Sci. 2010, 52, 152-160.
  5. Khersonsky, O.; Tawfik, D. S. Biochemistry 2005, 44, 6371-6382.
  6. Türkeş, C.; Söyüt, H.; Beydemir, Ş. Pharmacol. Rep. 2014, 66, 74-78.
  7. Türkeş, C.; Söyüt, H.; Beydemir, Ş. J. Enzyme Inhib. Med. Ch. 2015, 30, 622–628.
  8. Türkeş, C.; Söyüt, H.; Beydemir, Ş. Environ. Toxicol. Phar. 2016, 42, 252-257.
  9. Gaidukov, L.; Tawfik, D. S. Biochemistry 2005, 44, 11843-11854.
  10. Renault, F.; Chabriere, E.; Andrieu, J.P.; Dublet, B.; Massona, P.; Rochua, D. J. Chromatogyr. B, 2006, 836, 15-21.
  11. Aviram, M.; Rosenblat, M. Free Radical Bio. Med. 2004, 37, 1304–1316.
  12. Rozenberg, O.; Shih, S. D.; Aviram, M. Atherosclerosis 2005, 181, 9–18.
  13. Ekinci, D.; Beydemir, S. J. Enzyme Inhib. Med. Ch. 2009, 24, 1034-1039.
  14. Ekinci, D.; Beydemir, S. Eur. J. Pharmacol. 2009, 617, 84-89.
  15. Giamarellos-Bourboulis, E.J.; Antonopoulou, A.; Raftogiannis, M. Koutoukas P, Tsaganos, T., Tziortzioti, V., Panagou, C., Adamis, T., Giamarellou, H. BMC Infect. Dis. 2006, 21, 31.